Clinical Trials Logo

Soft Tissue Sarcoma Adult clinical trials

View clinical trials related to Soft Tissue Sarcoma Adult.

Filter by:

NCT ID: NCT06385288 Recruiting - Clinical trials for Soft Tissue Sarcoma Adult

Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

Start date: July 21, 2021
Phase: N/A
Study type: Interventional

"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging.

NCT ID: NCT06273852 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Start date: April 29, 2024
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.

NCT ID: NCT06252727 Not yet recruiting - Soft Tissue Sarcoma Clinical Trials

Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

This will be a prospective pilot study that will evaluate 20 patients who were diagnosed with FNCLCC Grade 2 or 3 soft tissue sarcomas and will undergo surgical resection. Based upon the FDA label, successful protocols used for intraoperative fluorescence-guided visualization for glioma resections, and on drug company current dosing recommendation for this study, patients will be administered 20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgery. The use of 5-ALA fluorescence will be relevant for evaluating the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.

NCT ID: NCT06110650 Not yet recruiting - Clinical trials for Soft Tissue Sarcoma Adult

A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

Start date: November 28, 2023
Phase: N/A
Study type: Interventional

This is a single-center, open, single-arm, phase II clinical study to investigate the efficacy and safety of patients with soft tissue sarcoma who have failed anthracycline-containing chemotherapy and whose antivascular agents have been effective and failed. Progression-free survival (PFS) was used as the primary outcome measure to preliminatively estimate the efficacy and safety of 29 patients with soft tissue sarcoma who had failed chemotherapy with anthracyclines and who had received effective and failed antivascular agents. Sofantinib 300mg orally, once a day, with continuous administration every 21 days, until the disease progresses or becomes intolerable; Imaging methods were used every 6 weeks (±7 days) after enrollment according to RECIST1.1 standard to evaluate the efficacy of tumor.

NCT ID: NCT05961761 Recruiting - Clinical trials for Undifferentiated Pleomorphic Sarcoma

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

PROPANE
Start date: August 17, 2021
Phase: Phase 2
Study type: Interventional

The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer: - Primary: determine the progression-free survival rate (PFSR) at 3 months Secondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL) • Exploratory: Characterize the TME Participants will be asked to ensure - Baseline biopsy and further optional biopsies - Treatment propranolol 40 mg BID and pembrolizumab 2 mg/kg Q3 weeks - Evaluation, blood counts, QoL and blood samples for biomarkers according to schedule

NCT ID: NCT05182164 Recruiting - Osteosarcoma Clinical Trials

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

PEMBROCABOSARC
Start date: April 25, 2022
Phase: Phase 2
Study type: Interventional

Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.

NCT ID: NCT05116254 Recruiting - Clinical trials for Soft Tissue Sarcoma Adult

Sarcomas and DDR-Inhibition; a Combined Modality Study

SADDRIN-1
Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering AZD1390 with or without durvalumab and RT concurrently treating newly diagnosed, non-metastatic soft tissue sarcoma patients with DDRi-based CMT, in the specific context of systemic toxicities, wound healing post-surgery and in defining the RP2D for the combinations to support further clinical evaluation.

NCT ID: NCT04656262 Recruiting - Clinical trials for Soft Tissue Sarcoma Adult

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

METROPHOLYS
Start date: September 10, 2018
Phase: Phase 3
Study type: Interventional

To compare the efficacy, as measured by time to treatment failure, of metronomic cyclophosphamide with respect to doxorubicin in elderly patients affected by mSTS.

NCT ID: NCT04617327 Recruiting - Clinical trials for Soft Tissue Sarcoma Adult

Pre-operative RadiothErapy for Soft Tissue SarcOmas

PRESTO
Start date: June 5, 2020
Phase: N/A
Study type: Interventional

Soft tissue sarcomas (STSs) are malignant tumours that arise in any of the mesodermal tissues in the body including muscles, fibrous tissues, bone and cartilage, adipose tissue, and blood vessels, most frequently in the extremities (40%), trunk and retroperitoneum (40%). Traditionally, the prescription schedule for conventional preoperative RT is a regimen of 50 Gy in fractions of 1.8-2 Gy per day. Concerns regarding this regimen include the delay to definitive surgery and the higher rate of wound complications compared to post-operative radiotherapy. Hypofractionated RT is a prescription schedule in which the total dose of radiation is delivered in larger doses per fraction in fewer fractions allowing the delivery of a higher biologically effective dose (BED) to the tumour than with conventional RT [7] during a shorter period of time.

NCT ID: NCT04577014 Active, not recruiting - Sarcoma Clinical Trials

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Start date: September 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that are commonly used to treat soft tissue sarcoma. Retifanlimab is an experimental drug that boosts the immune system's ability to fight cancer cells. The study researchers think that Retifanlimab may help gemcitabine and docetaxel work better against soft tissue sarcoma that is either locally advanced or has spread beyond its original location (metastasized), and it cannot be removed with surgery (unresectable).